Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by ScienceFirston Apr 17, 2023 7:29pm
134 Views
Post# 35399462

RE:Keytruda = $265,000 (17 doses per year)

RE:Keytruda = $265,000 (17 doses per year)Not impressive ... on any fronts 

Gemcitabine + Docetaxel = $172,000 (6 doses total)


Intravesical gemcitabine/docetaxel for NMIBC appears safe and efficacious


April 7, 2023

The efficacy and tolerability of Gem/Doce in this cohort study appear to be at least comparable, if not superior, to BCG. The BCG supply-and-demand equation is not likely be solved in the foreseeable future. Yet tens of thousands of patients with NMIBC will continue to require effective intravesical therapy in order to preserve the bladder and avoid radical cystectomy. The ongoing randomized clinical trials, such as the BRIDGE study (NCT05538663), comparing intravesical BCG and Gem/Doce, will provide invaluable insight into the effectiveness of this combination chemotherapy.

There are a few issues specific to Gem/Doce instillation, such as more complex workflow and longer encounter time, that need to be managed by the healthcare providers and clinic staff. When adequate BCG supply is available, it is still the preferred first-line therapy for high-risk NMIBC due to extensive experience with its known response rate and toxicity profile. However, out of necessity, Gem/Doce is being offered as the first-line intravesical therapy for newly diagnosed NMIBC at our center and many other centers. The current study is welcome news as it lends further support to the use of intravesical Gem/Doce as a safe and effective option which has the potential to become a new standard of care for high-risk NMIBC.

 

<< Previous
Bullboard Posts
Next >>